[对于他类药物不耐受性的N-of-1试验:临床实践中的可行性]
Léonore Diezi1, Thierry Buclin2, David Nanchen3
1Service de pharmacologie clinique, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue medicale suisse
|March 5, 2026
概括
N-of-1试验评估了在有不良反应的患者中对他类药物的个人耐受性. 结果表明有nocebo效应,导致患者恢复他类药物治疗,并改善了治疗的坚持.
科学领域:
- 临床药理学 临床药理学
- 基于证据的医学基于证据的医学.
- 患者报告的结果
背景情况:
- 经常报告说,他类药物不耐受,导致停止治疗.
- N-of-1试验提供了一个个性化的方法来评估药物耐受性.
- 诺塞博效应可能会导致药物不良反应的感知.
研究的目的:
- 评估N-of-1试验在报告不良反应的患者中评估他类药物耐受性的实用性.
- 调查nocebo效应在他类药物不耐受性中的作用.
- 在临床实践中证明N-of-1试验的可行性和影响.
主要方法:
- 一个由六名患者报告与他类药物相关的不良影响的病例系列.
- 个性化,随机化,安慰剂控制的N-of-1试验比较他类药物和比较剂.
- 评估患者报告的结果和治疗坚持.
主要成果:
- 在所有6名患者中,N-of-1试验显示,他类药物和比较药物之间没有显著差异.
- 结果表明nocebo效应是报告的不良事件的可能原因.
- 所有患者都选择在试验结束后恢复他类药物治疗.
- 在N-of-1试验过程中,治疗的坚持得到了增强.
结论:
- 在临床实践中,N-of-1试验是可行的,用于评估他类药物的耐受性.
- 这些试验可以识别nocebo效应并改善患者对他类药物治疗的坚持.
- N-of-1试验是一个有价值的,基于证据的工具,可以优化患者管理,尽管使用率不足.
相关概念视频
Clinical Trials
11.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.0K
Bioavailability Study Design: Healthy Subjects Versus Patients
195
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
195
Clinical Trials: Overview
5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Bioavailability Study Design: Single Versus Multiple Dose Studies
298
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
298
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Bioavailability Study Design: Absolute Versus Relative Bioavailability
484
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
484


